08:51 AM EDT, 03/16/2026 (MT Newswires) -- Structure Therapeutics ( GPCR ) said Monday that its aleniglipron clinical program to potentially treat people with obesity and/or overweight with co-morbidity achieved weight loss in a phase 2 trial and an open label extension study, with no evidence of weight loss plateau.

In the phase 2 study, the investigational GLP-1 receptor agonist showed a "clinically meaningful" and "statistically significant" placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16% at the 240 mg dose at 44 weeks, the company said.

Interim data from an open label extension study showed that aleniglipron achieved continued weight loss from 36 weeks and up to 16.2% at 120 mg dose at 56 weeks, the company said.

Structure said there has been no drug-induced liver injury, no persistent liver enzyme elevations and no QTc prolongation across the studies.

The company said it expects to finalize the phase 3 trial design during a meeting with the US Food and Drug Administration in Q2 and anticipates to initiate phase 3 in H2.

Shares of the company were up 9% in Monday premarket activity.